Indacaterol: a new long-acting β₂-agonist in the management of chronic obstructive pulmonary disease

Bibliography

• Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 2001;164:372-7
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990 – 2020: global Burden of Disease Study. Lancet 1997;349:1498-04
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org
   Google Scholar
• Michaud CM, Murray CJ, Bloom BR. Burden of disease-implications for future research. JAMA 2001;285:535-9
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117(Suppl 2):5S-9S
   PubMed Web of Science ®Google Scholar
• Geitona M, Hatzikou M, Steiropoulos P, The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med 2011;105:402-9
   PubMed Web of Science ®Google Scholar
• Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:5s-13s
   PubMedGoogle Scholar
• Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:367-70
   PubMedGoogle Scholar
• Calverley PM, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;22:775-89
   Google Scholar
• Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002;110:S298-303
   PubMedGoogle Scholar
• Calverley PM. Modern treatment of chronic obstructive pulmonary disease. Eur Respir J 2001;18:60s-6s
   Google Scholar
• Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-12
   PubMed Web of Science ®Google Scholar
• Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000;355:1931-5
   PubMed Web of Science ®Google Scholar
• Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:205-15
   PubMedGoogle Scholar
• Lombardi D, Cuenoud B, Kramer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009;38:533-47
   PubMed Web of Science ®Google Scholar
• Rosethorne E, Turner RJ, Fairhurst RA, Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiederbergs Arch Pharmacol 2010;382:255-63
   PubMed Web of Science ®Google Scholar
• Naline E, Trifilieff A, Fairhurst RA, Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007;29:575-81
   PubMed Web of Science ®Google Scholar
• Battram C, Charlton SJ, Cuenoud B, In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006;317:762-70
   PubMed Web of Science ®Google Scholar
• Sturton RG, Trifilief A, Nicholson AG, Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008;324:270-5
   PubMed Web of Science ®Google Scholar
• Duvauchelle T, Elharrar B, Knight H, Single dose indacaterol, a novel 24-h 2 agonist, is well-tolerated in patients with mild asthma. Eur Respir J 2005;26:253s
   Google Scholar
• Tarral A, Fauchaux N, Knight H, Safety and tolerability of multiple-dose indacaterol, a novel 2-agonist, in patients with mild asthma. Eur Respir J 2005;26:253s
   Google Scholar
• European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report EMA/659981/2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001114/WC500053735.pdf#]
   Google Scholar
• Beier J, Chanez P, Martinot JB, Safety, tolerability and efficacy of indacaterol, a novel once-daily 2-agonist, in patients with COPD: a 28-day randomised, placebo-controlled clinical trial. Pulm Pharmacol Ther 2007;20:740-9
   PubMed Web of Science ®Google Scholar
• Rennard S, Bantje T, Centanni S, A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-44
   PubMed Web of Science ®Google Scholar
• Bauwens O, Ninane V, Van de Maele B, 24-h bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009;25:463-70
   PubMed Web of Science ®Google Scholar
• Beier J, Beeh KM, Brookman L, Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22:492-6
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pocock SJ, Magnussen H, Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol vs twice-daily formoterol in COPD. Thorax 2010;65:473-9
   PubMed Web of Science ®Google Scholar
• Feldman G, Siler T, Prasad N, Efficacy and safety of indacaterol 150 mug once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010;10:11
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lotvall J, Once daily bronchodilators for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:155-62
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Ramos Bourbon D. Jack, D, et al. Indacaterol provides 24-h bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010;11:135
   PubMed Web of Science ®Google Scholar
• Magnussen H, Verkindre C, Jack D, Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010;104:1869-76
   PubMed Web of Science ®Google Scholar
• Kornmann O, Dahl R, Centanni S, Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9
   PubMed Web of Science ®Google Scholar
• LaForce C, Aumann J, de Teresa Parreno L, Sustained 24-h efficacy of once daily indacaterol (300 mcg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther 2011;24:162-8
   PubMed Web of Science ®Google Scholar
• Chapman KR, Rennard SI, Dogra A, Long-term safety and efficacy of indacaterol, a novel long-acting {beta}2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011;140:68-75
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Casaburi R, Vincken W, Effect of indacaterol on exercise and lung hyperinflation in COPD. Respir Med 2011;105:1030-6
   PubMed Web of Science ®Google Scholar
• Beeh KM, Wagner F, Khindri S, Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011;8(5):340-5
   PubMedGoogle Scholar
• Korn S, Kerwin E, Atis S, Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011;105:719-26
   PubMed Web of Science ®Google Scholar
• Balint B, Watz H, Amos C, Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010;5:311-18
   PubMedGoogle Scholar
• Buhl R, Dunn LJ, Disdier C, Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38:797-803
   PubMed Web of Science ®Google Scholar
• Khindri S, Sabo R, Harris S, Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011;11:31
   PubMedGoogle Scholar
• Worth H, Chung KF, Felser JM, Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105:571-9
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Kornmann O, Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92
   PubMed Web of Science ®Google Scholar
• Price D, Gray A, Gale R, Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011;105(11):1635-47
   PubMedGoogle Scholar